CN102772401A - 鼠尾草酚的抗骨质疏松新用途 - Google Patents
鼠尾草酚的抗骨质疏松新用途 Download PDFInfo
- Publication number
- CN102772401A CN102772401A CN2011102922077A CN201110292207A CN102772401A CN 102772401 A CN102772401 A CN 102772401A CN 2011102922077 A CN2011102922077 A CN 2011102922077A CN 201110292207 A CN201110292207 A CN 201110292207A CN 102772401 A CN102772401 A CN 102772401A
- Authority
- CN
- China
- Prior art keywords
- carnosol
- osteoporosis
- bone
- oestrogen
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 title claims abstract description 29
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 title claims abstract description 28
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 235000004654 carnosol Nutrition 0.000 title claims abstract description 28
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 10
- 206010030247 Oestrogen deficiency Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 21
- 239000011575 calcium Substances 0.000 abstract description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 12
- 229910052791 calcium Inorganic materials 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000000262 estrogen Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 230000008021 deposition Effects 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000008416 bone turnover Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 210000001672 ovary Anatomy 0.000 description 11
- 230000002146 bilateral effect Effects 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001009 osteoporotic effect Effects 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002956 ash Substances 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了鼠尾草酚用于防治骨质疏松的新用途。骨质疏松是危害人类健康的重要疾病之一，随着人口的老龄化，骨质疏松的病人日益增多，给全球带来了巨大的社会，医疗和经济负担。尽管国内外相关专家学者对此病的防治十分重视，但该病尚缺乏有效的治疗药物。本发明通过体内试验发现鼠尾草酚有显著抗骨质疏松的作用。实验结果表明鼠尾草酚能够抑制去卵巢引起的骨转化率增强，较少骨质破坏，同时可以提高血钙浓度，有利于骨的沉积。对于由于雌激素缺乏导致的骨质疏松具有治疗作用，并且无雌激素样副作用。
Description
技术领域
本发明涉及抗骨质疏松相关的药物领域，尤其涉及鼠尾草酚用于防治骨质疏松的新用途。
背景技术
骨质疏松是一种全身性的、代谢性的骨疾病，其特征是骨量减少和丢失，骨脆性和骨折危险性增加。随着人口的老龄化，骨质疏松的发病率也随着迅速增加，已经成为危害人类健康的重要疾病，并给全球带来了巨大的社会和经济负担。尽管国内外相关专家学者对此病的防治十分重视，但该病尚缺乏有效的治疗药物。
目前临床上常用的防治骨质疏松的药物包括雌激素替代药物，双膦酸盐类，选择性雌激素受体调节剂，维生素D，甲状旁腺素和人重组甲状旁腺激素(1-34) 等。双磷酸盐类药物虽然效果不错，但可导致颌骨坏死、肌肉骨骼痛和肾功能衰竭等严重不良反应；激素替代疗法虽然是防治绝经后骨质疏松的重要方法，但长期使用有导致乳腺癌、子宫内膜癌的潜在危险且发生血栓的风险也增加；而选择性雌激素受体调节剂可以使血栓性事件明显增加。其他药物或价格昂贵，或远期疗效不确切，均不够理想。由于骨质疏松是一种慢性病，需要长期服药，因此价格便宜，毒副作用小的中草药已成为研究治疗骨质疏松的热点之一。
鼠尾草酚是从迷迭香原料中提取的一种天然化合物，具有抗氧化、抗炎和抗癌的作用，并未发现鼠尾草酚有抗骨质疏松用途。
发明内容
本发明提供鼠尾草酚的抗骨质疏松新用途。
本发明通过体内实验发现鼠尾草酚在制备抗骨质疏松药物中的应用。
进一步，所述的骨质疏松是由于雌激素缺乏导致。
本发明通过体内试验发现鼠尾草酚有显著的预防骨质疏松的作用。鼠尾草酚能够抑制去卵巢引起的骨转化率增强和骨质破坏，同时可以提高血钙浓度，有利于骨的沉积。是一种理想的防治骨质疏松的药物。
具体实施方式
1、材料与方法
将十周龄健康SD雌鼠（18只，江苏省动物中心）随机分成3组，每组6只：假手术组（Sham）、卵巢切除模型组（OVX）、鼠尾草酚组（CAR）。饲养条件：温度为(23 ±2) ℃，光照:黑暗为12∶12 。让各组大鼠适应环境2周后开始骨质疏松造模手术：各组大鼠均经腹腔注射20%乌拉坦麻醉(6ml/ kg 体重)，Sham组开腹后关腹，其余两组行双侧卵巢切除术。术后第4周起，Sham组和OVX组每天进食标准饲料和去离子水，CAR组每天进食加工过的含有0.1%鼠尾草酚的鼠粮，连续3个月，每周称一次体重。实验结束后，用乌拉坦麻醉，摘取眼球采血，2000r/min离心，吸取上清（即血清）。摘除大鼠子宫，迅速称重。取出大鼠双侧股骨和双侧胫骨，剔除软组织。两胫骨经800℃高温炉（由南京大学化学化工学院提供）中灰化8 h，冷却后称灰重。用研钵碾碎成灰状，取0.1g 骨灰溶于1 ml, 6 mol/l盐酸中，测骨钙和骨磷时取0.2 ml用超纯水稀释至1ml，用全自动生化分析仪检测骨钙和骨磷含量。左股骨用骨密度仪（江苏省人民医院核医学科提供）测量骨密度（BMD）。血清生化指标测定：取血清0.5 ml，用全自动生化分析仪（南京军区南京总医院普外科提供）检测血清碱性磷酸酶（ALP）、钙（Ca）和磷（P）。实验结果用 x±S表示。
2、结果
表1 鼠尾草酚对双侧卵巢切除大鼠体重及子宫系数的的影响
| 实验组别 | 体重 (g) | 子宫指数(mg/g) |
| Sham | 345.7±54.4 | 1.894±0.95 |
| OVX | 345.0±41.9 | 0.141±0.59 |
| CAR | 343.1±18.8 | 0.236±1.11 |
表1显示各组大鼠体重无明显差别，去卵巢模型组大鼠的子宫明显萎缩，给予鼠尾草酚3个月后，并未引起子宫重量的明显增加，说明鼠尾草酚对子宫生长无刺激作用。
表2 鼠尾草酚对双侧卵巢切除大鼠血清ALP，血清Ca和血清P的的影响
| 实验组别 | 血清ALP (U/L) | 血清Ca (mmol/L) | 血清P (mmol/L) |
| sham | 29.00±8.49 | 2.50±0.14 | 2.00±0.19 |
| OVX | 221.00±19.80 | 2.30±0.04 | 1.47±0.22 |
| CAR | 70.00±10.18 | 2.72±0.08 | 1.51±0.19 |
从表2可以看出去卵巢后，模型组大鼠血清碱性磷酸酶活性增加。去卵巢后，体内雌激素缺乏，导致骨转化率增加，与绝经后妇女的高转化型骨质疏松症一致。给予鼠尾草酚3个月后，碱性磷酸酶活性显著下降，可见鼠尾草酚可以抑制去卵巢引起的骨转化率的增加，减少骨质的破坏。表中还显示与假手术组相比，模型组大鼠血清钙明显下降，而鼠尾草酚可显著提升血清钙浓度。血清钙是骨形成的重要标记物，说明鼠尾草酚可以有效逆转由于卵巢切除导致的血清钙的降低，有利于骨的形成。
表3鼠尾草酚对双侧卵巢切除大鼠左股骨BMD的的影响
| 实验组别 | 左股骨BMD(g/cm2) |
| sham | 0.332±0.027 |
| OVX | 0.215±0.037 |
| CAR | 0.2525±0.025 |
从表3可以看出去卵巢后模型组大鼠左股骨骨密度较假手术组显著下降，给予鼠尾草酚3个月后，骨密度有所增加。
表4 鼠尾草酚对双侧卵巢切除大鼠双侧胫骨参数的影响
| 实验组别 | 双胫骨骨钙(g/g) | 双胫骨骨磷(g/g) | 双胫骨灰重（g） |
| Sham | 0.2560±0.0003 | 0.2552±0.0016 | 0.765±0.106 |
| OVX | 0.2567±0.0027 | 0.2585±0.0027 | 0.617±0.023 |
| CAR | 0.2576±0.0026 | 0.2576±0.0026 | 0.648±0.047 |
从表4可以看出与假手术组相比，模型组大鼠双胫骨灰重显著降低，而鼠尾草酚较模型组有所升高。各组骨钙和骨磷含量没有明显差别。
以上实验结果表明鼠尾草酚能够抑制去卵巢引起的骨转化率增强和骨质破坏，同时可以提高血钙浓度，有利于骨的沉积。对于由于雌激素缺乏导致的骨质疏松具有防治作用，并且无雌激素样副作用。
Claims (2)
1.鼠尾草酚在制备抗骨质疏松药物中的应用。
2.根据权利要求1所述的应用，其特征在于：所述的骨质疏松是由于雌激素缺乏导致。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102922077A CN102772401A (zh) | 2011-10-02 | 2011-10-02 | 鼠尾草酚的抗骨质疏松新用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102922077A CN102772401A (zh) | 2011-10-02 | 2011-10-02 | 鼠尾草酚的抗骨质疏松新用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102772401A true CN102772401A (zh) | 2012-11-14 |
Family
ID=47117665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102922077A Pending CN102772401A (zh) | 2011-10-02 | 2011-10-02 | 鼠尾草酚的抗骨质疏松新用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772401A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460185A (zh) * | 2006-04-03 | 2009-06-17 | 雀巢产品技术援助有限公司 | 用于促进骨生长和维持骨健康的营养组合物及与其有关的方法 |
| WO2011031601A2 (en) * | 2009-09-14 | 2011-03-17 | Nestec S.A. | Nutritional compositions including exogenous vitamin k2 |
-
2011
- 2011-10-02 CN CN2011102922077A patent/CN102772401A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460185A (zh) * | 2006-04-03 | 2009-06-17 | 雀巢产品技术援助有限公司 | 用于促进骨生长和维持骨健康的营养组合物及与其有关的方法 |
| WO2011031601A2 (en) * | 2009-09-14 | 2011-03-17 | Nestec S.A. | Nutritional compositions including exogenous vitamin k2 |
| WO2011031601A3 (en) * | 2009-09-14 | 2011-06-03 | Nestec S.A. | Nutritional compositions including exogenous vitamin k2 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101925357B (zh) | 含有钙、镁、锌和维生素d3并能预防和改善骨质疏松症的组合物 | |
| CN104605226A (zh) | 一种具有增加骨密度功能的保健品 | |
| Sakat et al. | Osteoporosis: The brittle bone | |
| CN103349674B (zh) | 一种增加骨密度、防治骨质疏松症的龟甲林蛙油组合物 | |
| CN108938989B (zh) | 一种治疗骨质疏松症的覆茴精健骨散 | |
| AU2017203767A1 (en) | Method for filling bone cavity formations with calcium | |
| CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
| CN110301647A (zh) | 地龙蛋白复合低聚肽营养品 | |
| CN102920713B (zh) | Gypensapogenin B在制备抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102772401A (zh) | 鼠尾草酚的抗骨质疏松新用途 | |
| CN103127066A (zh) | Eryngiolide A在抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102772421B (zh) | 雷公藤甲素的抗骨质疏松用途 | |
| CN103127092A (zh) | Aphanamixoid A在抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN103356602B (zh) | Chukrasone B在制备抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102895237B (zh) | Gypensapogenin A在抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102988385B (zh) | Houttuynoid A在制备抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102949712A (zh) | 一种治疗肿瘤疾病的中西复合药物 | |
| CN103356572A (zh) | Sarcaboside B在制备抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN102988391A (zh) | Houttuynoid E在制备抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN103393650A (zh) | Sarcaboside A在抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN103356660A (zh) | Chukrasone A在抗雌激素缺乏导致的骨质疏松药物中的应用 | |
| CN106075407B (zh) | 一种功能性钙制剂及其制备方法 | |
| CN104523685A (zh) | 去铁斯若在制备治疗绝经后骨质疏松疾病药物中的用途 | |
| Touyz et al. | Osteoporosis as it Affects Men, Andropausal and Senior Males | |
| CN103251935A (zh) | 一种含有鹿茸的药用组合物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121114 |